Emily Caro-Bruce, MD
Family Practice · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 20 years
- Warren Alpert Medical School of Brown University, 2006
Offices
1 location · One Medical Group Inc · 330 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Caro-Bruce’s office at (888) 663-6331 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A114203 · Current
Licensed to practise in California · since 2010 · expires 2028-06-30 · Brown University Program in Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MDRE.ML.20008551Physician And Surgeon Residency Limited License · since 2006 · expires 2008-07-31ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$43,510
Medicare paid this office $43,510 for 206 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 71 | $18,708 | $111 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 28 | $4,364 | $156 |
| Short return visit (20+ min) | 37 | $3,731 | $75 |
| Sarscov2 vac 50 mcg/0.5ml im | 15 | $2,365 | $148 |
| Insertion of needle into vein for collection of blood sample | 156 | $1,920 | $9 |
See all 9 services
| Return visit (30+ min) | 71 | $18,708 | $111 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 28 | $4,364 | $156 |
| Short return visit (20+ min) | 37 | $3,731 | $75 |
| Sarscov2 vac 50 mcg/0.5ml im | 15 | $2,365 | $148 |
| Insertion of needle into vein for collection of blood sample | 156 | $1,920 | $9 |
| Influenza vaccine split virus, preservative free | 21 | $1,780 | $81 |
| Administration of influenza virus vaccine | 22 | $890 | $39 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 32 | $843 | $15 |
| Admn sarscov2 vacc 1 dose | 15 | $825 | $52 |
Who their Medicare patients are
206 Original Medicare patients in 2024. Average age 74 · Women 55% · Health risk score 0.92. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 49% · Cancer 17% · Depression 17% · Coronary heart disease 14% · Diabetes 12% · Chronic kidney disease 12% · Atrial fibrillation 8% · COPD 6% · Heart failure 5%.
The office billed $262,985, Medicare allowed $54,258 and paid $43,510; for 697 services of 30 kinds; $6,703 of it was for drugs given in the office and $36,808 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 206 | 697 | 74 | 0.92 | $262,985 | $43,510 |
| 2023 | 163 | 503 | 73 | 0.86 | $197,115 | $34,010 |
| 2022 | 139 | 347 | 72 | 0.76 | $142,185 | $27,964 |
| 2021 | 138 | 331 | 73 | 0.91 | $132,559 | $26,066 |
| 2020 | 181 | 433 | 72 | 0.88 | $127,510 | $25,578 |
| 2019 | 112 | 253 | 72 | 1.06 | $97,647 | $16,859 |
| 2018 | 96 | 216 | 70 | 0.72 | $81,520 | $16,115 |
| 2017 | 52 | 129 | 70 | 0.70 | $37,440 | $7,594 |
| 2016 | 27 | 54 | 70 | 0.76 | $23,144 | $4,217 |
| 2015 | 20 | 27 | 65 | 0.57 | $9,144 | $2,350 |
| 2014 | 12 | 20 | 62 | 1.91 | $4,467 | $1,183 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 54 | $14,630 | $118 |
| Short return visit (20+ min) | 42 | $4,860 | $81 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | $2,906 | $153 |
| Influenza vaccine split virus, preservative free | 35 | $2,518 | $72 |
| Insertion of needle into vein for collection of blood sample | 117 | $1,310 | $8 |
| Administration of influenza virus vaccine | 36 | $1,306 | $36 |
2022: 7 services
| Return visit (30+ min) | 45 | $9,556 | $112 |
| Short return visit (20+ min) | 42 | $4,889 | $81 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 41 | $2,876 | $70 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 14 | $2,154 | $154 |
| Administration of influenza virus vaccine | 55 | $1,983 | $36 |
| Influenza vaccine, quadrivalent derived from recombinant dna | 13 | $891 | $69 |
| Urinalysis, manual test | 11 | $38 | $3 |
2021: 8 services
| Return visit (30+ min) | 55 | $10,267 | $104 |
| Short return visit (20+ min) | 28 | $3,062 | $75 |
| Long return visit (40+ min) | 18 | $3,059 | $170 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 15 | $2,352 | $157 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 22 | $1,461 | $66 |
| Administration of influenza virus vaccine | 28 | $586 | $21 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; third dose | 14 | $560 | $40 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose | 26 | $444 | $17 |
2020: 9 services
| Return visit (30+ min) | 52 | $8,189 | $94 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 66 | $4,026 | $61 |
| Short return visit (20+ min) | 41 | $3,622 | $57 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 15 | $2,065 | $138 |
| Administration of influenza virus vaccine | 90 | $1,853 | $21 |
| Pneumococcal vaccine, 23-valent | 11 | $1,295 | $118 |
| Influenza vaccine split virus, preservative free | 17 | $1,037 | $61 |
| Short return visit | 14 | $775 | $52 |
| Administration of pneumococcal vaccine | 12 | $246 | $20 |
2019: 4 services
| Return visit (30+ min) | 61 | $8,756 | $86 |
| Short return visit (20+ min) | 43 | $2,841 | $48 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $1,645 | $137 |
| Administration of influenza virus vaccine | 13 | $262 | $20 |
2018: 5 services
| Return visit (30+ min) | 43 | $4,998 | $86 |
| Short return visit (20+ min) | 29 | $2,496 | $62 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 15 | $1,995 | $133 |
| Influenza vaccine split virus, preservative free | 23 | $1,199 | $52 |
| Administration of influenza virus vaccine | 28 | $708 | $25 |
2017: 4 services
| Return visit (30+ min) | 18 | $2,561 | $83 |
| Influenza vaccine split virus, preservative free | 26 | $1,249 | $48 |
| Administration of influenza virus vaccine | 28 | $906 | $32 |
| Short return visit (20+ min) | 13 | $884 | $52 |
Drugs they prescribed that Part D paid
$83,142
Pharmacies billed $83,142 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (13 of 711) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
622 generic and fewer than 11 brand-name prescriptions · $83,142 in drug cost · 19 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 27 | $32,298 | $1,196 |
| Atorvastatin | 83 | $1,138 | $14 |
| Levothyroxine | 50 | $700 | $14 |
| Losartan | 30 | $583 | $19 |
| Olanzapine | 12 | $476 | $40 |
See all 15 drugs
| Ozempic | 27 | $32,298 | $1,196 |
| Atorvastatin | 83 | $1,138 | $14 |
| Levothyroxine | 50 | $700 | $14 |
| Losartan | 30 | $583 | $19 |
| Olanzapine | 12 | $476 | $40 |
| Metformin Hcl Er | 11 | $364 | $33 |
| Rosuvastatin | 22 | $350 | $16 |
| Escitalopram | 18 | $340 | $19 |
| Gabapentin | 14 | $277 | $20 |
| Duloxetine | 11 | $247 | $22 |
| Trazodone | 17 | $208 | $12 |
| Lisinopril | 15 | $183 | $12 |
| Amlodipine Besylate | 27 | $157 | $6 |
| Hydrochlorothiazide | 12 | $68 | $6 |
| Lorazepam | 11 | $20 | $2 |
Year by year
| 2024 | 711 | 94 | 2% (13) | None | $83,142 |
| 2023 | 555 | 89 | 3% (15) | None | $63,287 |
| 2022 | 479 | 76 | 3% (15) | None | $43,628 |
| 2021 | 471 | 72 | 3% (12) | 12% | $33,430 |
| 2020 | 407 | 82 | 3% (13) | None | $36,420 |
| 2019 | 258 | 50 | 5% (12) | 23% | $18,608 |
| 2018 | 192 | 39 | None | None | $12,341 |
| 2017 | 227 | 47 | None | None | $30,929 |
| 2016 | 319 | 74 | None | None | $18,990 |
| 2015 | 936 | 160 | 2% (22) | None | $39,098 |
| 2014 | 1,783 | 215 | 8% (133) | 22% | $92,960 |
| 2013 | 1,389 | 181 | 6% (89) | None | $61,961 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Ozempic | 18 | $20,319 | $1,129 |
| Estradiol | 12 | $2,898 | $242 |
| Atorvastatin | 45 | $941 | $21 |
| Levothyroxine | 37 | $709 | $19 |
| Escitalopram | 19 | $555 | $29 |
| Rosuvastatin | 18 | $440 | $24 |
| Losartan | 18 | $386 | $21 |
| Albuterol Sulfate Hfa | 11 | $310 | $28 |
| Metoprolol | 15 | $266 | $18 |
| Fluticasone Propionate | 12 | $115 | $10 |
| Amlodipine Besylate | 16 | $106 | $7 |
| Hydrochlorothiazide | 16 | $105 | $7 |
| Lisinopril | 12 | $94 | $8 |
2022: 12 drugs
| Eliquis | 14 | $11,096 | $793 |
| Rosuvastatin | 18 | $1,060 | $59 |
| Escitalopram | 19 | $1,019 | $54 |
| Levothyroxine | 48 | $865 | $18 |
| Atorvastatin | 43 | $681 | $16 |
| Losartan | 11 | $257 | $23 |
| Amlodipine Besylate | 24 | $206 | $9 |
| Metoprolol | 13 | $194 | $15 |
| Lovastatin | 11 | $171 | $16 |
| Lisinopril | 22 | $163 | $7 |
| Hydrocodone-Acetaminophen | 12 | $159 | $13 |
| Alendronate | 15 | $123 | $8 |
2021: 11 drugs
| Atorvastatin | 53 | $748 | $14 |
| Levothyroxine | 31 | $581 | $19 |
| Escitalopram | 16 | $359 | $22 |
| Alendronate | 29 | $352 | $12 |
| Olanzapine | 13 | $304 | $23 |
| Lovastatin | 16 | $260 | $16 |
| Divalproex | 13 | $142 | $11 |
| Amlodipine Besylate | 23 | $127 | $6 |
| Losartan | 11 | $103 | $9 |
| Hydrochlorothiazide | 13 | $93 | $7 |
| Metformin | 11 | $46 | $4 |
2020: 11 drugs
| Premarin | 12 | $3,745 | $312 |
| Levothyroxine | 20 | $625 | $31 |
| Atorvastatin | 29 | $448 | $15 |
| Olanzapine | 11 | $246 | $22 |
| Omeprazole | 11 | $233 | $21 |
| Lisinopril | 12 | $181 | $15 |
| Fluoxetine | 17 | $165 | $10 |
| Hydrocodone-Acetaminophen | 12 | $136 | $11 |
| Divalproex | 11 | $104 | $9 |
| Hydrochlorothiazide | 11 | $52 | $5 |
| Amlodipine Besylate | 11 | $29 | $3 |
2019: 3 drugs
| Levothyroxine | 24 | $606 | $25 |
| Atorvastatin | 19 | $217 | $11 |
| Fluoxetine | 12 | $195 | $16 |
2018: 1 drug
| Levothyroxine | 18 | $442 | $25 |
2017: 3 drugs
| Levothyroxine | 31 | $781 | $25 |
| Atorvastatin | 17 | $522 | $31 |
| Lisinopril | 16 | $119 | $7 |
2016: 7 drugs
| Atorvastatin | 23 | $686 | $30 |
| Levothyroxine | 19 | $466 | $25 |
| Ranitidine | 18 | $207 | $12 |
| Lisinopril | 17 | $179 | $11 |
| Amlodipine Besylate | 16 | $172 | $11 |
| Fluticasone Propionate | 12 | $166 | $14 |
| Simvastatin | 12 | $56 | $5 |
2015: 23 drugs
| Dulera | 20 | $5,285 | $264 |
| Atorvastatin | 73 | $2,141 | $29 |
| Levothyroxine | 50 | $1,522 | $30 |
| Losartan | 44 | $1,277 | $29 |
| Amlodipine Besylate | 39 | $807 | $21 |
| Fluticasone Propionate | 34 | $765 | $22 |
| Proair Hfa | 20 | $707 | $35 |
| Simvastatin | 39 | $698 | $18 |
| Clopidogrel | 11 | $641 | $58 |
| Lisinopril | 43 | $497 | $12 |
| Atenolol | 36 | $476 | $13 |
| Hydrocodone-Acetaminophen | 14 | $459 | $33 |
| Ranitidine | 31 | $435 | $14 |
| Hydrochlorothiazide | 31 | $344 | $11 |
| Metformin | 27 | $303 | $11 |
| Pantoprazole | 13 | $272 | $21 |
| Famotidine | 13 | $255 | $20 |
| Lovastatin | 19 | $219 | $12 |
| Metoprolol | 20 | $186 | $9 |
| Lisinopril-Hydrochlorothiazide | 14 | $148 | $11 |
| Furosemide | 15 | $138 | $9 |
| Sertraline | 17 | $131 | $8 |
| Citalopram Hbr | 15 | $127 | $8 |
2014: 41 drugs
| Dulera | 43 | $11,671 | $271 |
| Humalog | 18 | $3,277 | $182 |
| Zostavax | 17 | $3,145 | $185 |
| Atorvastatin | 79 | $2,537 | $32 |
| Losartan | 59 | $1,780 | $30 |
| Hydrocodone-Acetaminophen | 74 | $1,714 | $23 |
| Proair Hfa | 43 | $1,520 | $35 |
| Simvastatin | 88 | $1,470 | $17 |
| Levothyroxine | 71 | $1,443 | $20 |
| Qvar | 17 | $1,361 | $80 |
| Oxycodone-Acetaminophen | 20 | $1,065 | $53 |
| Amlodipine Besylate | 58 | $1,058 | $18 |
| Fluticasone Propionate | 44 | $1,041 | $24 |
| Clopidogrel | 22 | $1,001 | $45 |
| Lisinopril | 87 | $875 | $10 |
| Humulin N | 12 | $859 | $72 |
| Quetiapine | 13 | $816 | $63 |
| Omeprazole | 17 | $800 | $47 |
| Atenolol | 63 | $783 | $12 |
| Donepezil | 15 | $669 | $45 |
| Tamsulosin | 11 | $529 | $48 |
| Pantoprazole | 28 | $517 | $18 |
| Sertraline | 22 | $469 | $21 |
| Alendronate | 31 | $462 | $15 |
| Acetaminophen-Codeine | 21 | $455 | $22 |
| Hydrochlorothiazide | 40 | $448 | $11 |
| Lovastatin | 32 | $384 | $12 |
| Glipizide | 37 | $375 | $10 |
| Triamcinolone Acetonide | 15 | $345 | $23 |
| Ranitidine | 21 | $338 | $16 |
| Allopurinol | 12 | $327 | $27 |
| Metformin | 29 | $317 | $11 |
| Metoprolol | 30 | $289 | $10 |
| Citalopram Hbr | 27 | $238 | $9 |
| Lisinopril-Hydrochlorothiazide | 20 | $219 | $11 |
| Fluoxetine | 21 | $209 | $10 |
| Ibuprofen | 13 | $206 | $16 |
| Warfarin | 14 | $203 | $15 |
| Furosemide | 24 | $186 | $8 |
| Ciprofloxacin | 16 | $137 | $9 |
| Temazepam | 11 | $129 | $12 |
2013: 34 drugs
| Dulera | 19 | $4,654 | $245 |
| Humalog | 14 | $2,470 | $176 |
| Simvastatin | 98 | $1,822 | $19 |
| Losartan | 55 | $1,517 | $28 |
| Quetiapine | 11 | $1,162 | $106 |
| Atorvastatin | 36 | $1,145 | $32 |
| Levothyroxine | 52 | $1,119 | $22 |
| Hydrocodone-Acetaminophen | 53 | $1,096 | $21 |
| Clopidogrel | 15 | $1,043 | $70 |
| Lisinopril | 95 | $956 | $10 |
| Fluticasone Propionate | 34 | $940 | $28 |
| Proair Hfa | 27 | $882 | $33 |
| Donepezil | 18 | $829 | $46 |
| Omeprazole | 19 | $816 | $43 |
| Dilt-Xr | 11 | $755 | $69 |
| Amlodipine Besylate | 34 | $743 | $22 |
| Atenolol | 43 | $532 | $12 |
| Hydrochlorothiazide | 38 | $416 | $11 |
| Sertraline | 24 | $407 | $17 |
| Glipizide | 39 | $387 | $10 |
| Triamcinolone Acetonide | 16 | $376 | $23 |
| Oxycodone-Acetaminophen | 15 | $369 | $25 |
| Metformin | 32 | $359 | $11 |
| Lovastatin | 29 | $357 | $12 |
| Alendronate | 19 | $283 | $15 |
| Furosemide | 28 | $278 | $10 |
| Fluoxetine | 20 | $191 | $10 |
| Citalopram Hbr | 14 | $178 | $13 |
| Ranitidine | 12 | $172 | $14 |
| Acetaminophen-Codeine | 11 | $168 | $15 |
| Lisinopril-Hydrochlorothiazide | 15 | $143 | $10 |
| Ibuprofen | 11 | $140 | $13 |
| Ciprofloxacin | 15 | $122 | $8 |
| Metoprolol | 13 | $120 | $9 |
Professional record
- NPI
- 1164633806
- Licence
- CA A114203, NY 254734, WA ML20008551California A114203: Current · expires 2028-06-30Washington MDRE.ML.20008551: Expired
- Trained
- Warren Alpert Medical School of Brown University, 2006 · 20 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 130 Sutter St Fl 2, San Francisco, CA, 94104
- NPI first listed
- 2007-05-24
- NPI last updated
- 2025-03-17
- NPI record certified
- 2025-03-17
This is when the NPI record was last certified, not a medical board exam.